11th International AIDS Conference Vancouver, British Columbia — July 7-12, 1996

Int Conf AIDS 1996 Jul 7-12; 11:28 (abstract no. LB.B.6030)
Hirschel BJ, Rutschmann O, Fathi M, Gabriel V, Mendoula A, von Overbeck I, Iten A; Divisions of Infectious Diseases, University Hospitals, Geneva, Switzerland.

OBJECTIVES: To conduct a pilot study of the rit/saq combination in advanced HIV infection. Patients: 7 patients with median CD4 count of 10, all with previous AIDS-defining conditions, 5 with active disease (multiple drug-resistant TB with positive blood cultures, microsporidiosis, cryptosporidiosis, MOTT, progressing Kaposi's), and with serious previous adverse effects of nucleoside RT inhibitors, were treated with rit 600 mg b.i.d. from day 1-7. From day 8-14, saq, 200 mg bid was added, increased to 600 mg bid after day 15. Rit was tolerated by all patients; nausea necessitated a transitory decrease in dosage for one. Adding saq did not cause notable side effects; in particular, liver function tests, creatinine, bilirubin did not change. (Table: see text)

CONCLUSIONS: Rit/Saq was well tolerated by these patients with extremely advanced HIV infections, and produced a marked antiviral effect.

960707
LBB6030

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.